REVIEW ARTICLE

Unlocking the Genetic Code: Pharmacogenomics and the Potential of Personalized Medicine

Showbharnikhaa S[1], Vijayalakshmi M.K[2], Akshaya T[1]

[1]*Student, Faculty of Pharmacy, Bharath Institute of Higher Education and Research, Chennai, Tamil Nadu, India*
[2]*Associate Professor, Faculty of Pharmacy, Bharath Institute of Higher Education and Research, Chennai, Tamil Nadu, India.*

Abstract: Pharmacogenomics, situated at the nexus of genomics and pharmacology, represents a paradigm shift in healthcare by advocating personalized medicine over conventional one-size-fits-all drug therapy. This review article covers the origins, core principles, and current developments in pharmacogenomics, tracing its inception to the completion of the Human Genome Project. By investigating how genetic variations influence individual responses to medications, pharmacogenomics addresses the persistent challenge of inter-individual variability in drug efficacy, toxicity, and adverse reactions. Emphasis is placed on the pivotal role of key drug-metabolizing enzymes, notably the cytochrome P450 family, in shaping drug responses. The review provides historical milestones and foundational principles, offering a comprehensive understanding of the intricate interplay between genetics and drug response. As we decode the genetic blueprint, the potential to tailor drug regimens based on individual genetic profiles becomes increasingly feasible. The evolving landscape of pharmacogenomics holds promise in optimizing drug outcomes and minimizing adverse effects, ushering in a new era of patient-centered healthcare.

Keywords: Pharmacogenomics; Genetic variations; Cytochrome oxidases; Health care; Drug optimization.

1. Introduction

Pharmacogenomics, a dynamic intersection of genomics and pharmacology, stands at the forefront of a groundbreaking shift in healthcare paradigms. Unlike the traditional one-size-fits-all approach to drug therapy, pharmacogenomics seeks to unravel the genetic underpinnings of individual responses to medications, heralding a new era of personalized medicine. At its core, pharmacogenomics explores how an individual's genetic makeup influences their susceptibility to diseases and responses to pharmacological interventions [1, 2]. The journey of pharmacogenomics began with the Human Genome Project's completion, marking a pivotal moment in our understanding of the genetic blueprint that orchestrates human life. This field capitalizes on this wealth of genomic information, investigating how genetic variations among individuals contribute to diverse drug responses. Crucially, pharmacogenomics addresses the longstanding clinical challenge of inter-individual variability in drug efficacy, toxicity, and adverse reactions. Genetic variations in key drug-metabolizing enzymes, such as the cytochrome P450 family, play a central role in pharmacogenomics. These enzymes govern the conversion of drugs into active or inactive forms, influencing their bioavailability and therapeutic effects. As we uncover the intricate interplay between genetics and drug response, the potential to tailor drug regimens to an individual's genetic profile becomes increasingly tangible. This review navigates through the historical milestones, foundational principles, and emerging trends in pharmacogenomics [3, 4]. By deciphering the genetic code, we aim to unlock a treasure trove of insights that can inform more precise and effective therapeutic strategies. As pharmacogenomics continues to evolve, its promise to optimize drug outcomes and minimize adverse effects holds the potential to revolutionize the landscape of patient-centered healthcare.

2. Pharmacogenomics and Personalized medicine- A paradigm shift

2.1. Genetic variability in drug response

The complex mechanisms of human genetics contributes significantly to the variability observed in individual responses to pharmacotherapy. The Human Genome Project, a cornerstone in genomic research, paved the way for understanding the genetic basis of inter-individual differences in drug responses [5]. Genetic polymorphisms in key drug-metabolizing enzymes and transporters introduce diversity in drug metabolism. The cytochrome P450 superfamily, encompassing various isoforms, plays a central role in the biotransformation of a myriad of drugs. Variations in these enzymes result in altered rates of drug metabolism, leading to differences in drug efficacy and toxicity among individuals. Similarly, genetic variations in drug transporters, which govern

the movement of drugs across cellular membranes, contribute to variations in drug absorption and distribution [6]. This genetic variability is not limited to enzymes and transporters; it extends to drug targets and receptors, influencing the downstream pharmacological effects. As we unravel the genetic code's impact on drug response, the prospect of tailoring drug regimens to individual genotypes gains momentum. By decoding genetic variability in drug response, clinicians can optimize treatment plans, mitigate adverse effects, and pave the way for a more personalized and effective approach to pharmacotherapy [7]. The exploration of these genetic nuances holds the promise of unlocking tailored therapeutic strategies that can enhance patient outcomes and redefine the landscape of modern medicine. [15-18]

2.2. Clinical application of pharmacogenomics

The integration of pharmacogenomics into clinical practice marks a transformative leap toward precision medicine, revolutionizing the conventional approach to drug therapy. This section explores the tangible clinical applications of pharmacogenomics, elucidating how genetic information is harnessed to tailor drug regimens and optimize patient outcomes. In the realm of oncology, pharmacogenomics plays a pivotal role in tailoring cancer treatments based on the unique genetic profiles of individuals [8]. Genetic markers guide the selection of chemotherapy agents, dosages, and the prediction of adverse reactions, allowing oncologists to customize treatment strategies for maximum efficacy while minimizing side effects. Beyond oncology, pharmacogenomics testing is increasingly being applied in cardiovascular medicine. Genetic variations impacting the metabolism of anticoagulants and antiplatelet agents contribute to diverse responses among patients [9]. By identifying these genetic factors, clinicians can optimize the selection and dosing of cardiovascular medications, reducing the risk of adverse events and improving overall treatment outcomes. Psychiatric medications, notorious for their variable response rates and side effects, present another frontier for pharmacogenomics. Genetic insights into drug metabolism and receptor interactions empower psychiatrists to tailor psychotropic medications based on an individual's genetic profile, potentially enhancing treatment response and minimizing adverse effects. The clinical implementation of pharmacogenomics involves incorporating genetic testing into routine patient care, enabling healthcare providers to make informed decisions about drug selection and dosing. This section also delves into success stories, illustrating instances where pharmacogenomics data has led to improved patient outcomes and enhanced medication management. Despite these advancements, challenges persist, including the need for standardized guidelines, increased awareness among healthcare professionals, and addressing ethical considerations. As pharmacogenomics continues to weave its way into the fabric of clinical practice, the potential to deliver truly personalized medicine is becoming a reality, promising a future where treatment decisions are not only evidence-based but also uniquely tailored to the genetic makeup of each patient [19-21]

2.3. Pharmacogenomics in oncology

The convergence of pharmacogenomics and oncology represents a paradigm shift in the way we approach cancer treatment. This section delves into the intricate landscape of pharmacogenomics in oncology, highlighting its profound impact on tailoring therapies and improving outcomes for cancer patients. One of the primary applications of pharmacogenomics in oncology is the identification of genetic markers that influence drug metabolism and response [11]. By analyzing an individual's genetic profile, oncologists can predict how a patient will metabolize specific chemotherapy agents. This enables the selection of the most effective drugs while minimizing the risk of adverse reactions, ultimately enhancing the overall safety and efficacy of cancer treatment. The emergence of targeted therapies is a hallmark achievement in oncology, and pharmacogenomics plays a pivotal role in their success. These therapies are designed to specifically target molecular aberrations driving cancer growth. Pharmacogenomics testing helps identify patients with the specific genetic alterations that make them candidates for these targeted treatments, ushering in a new era of precision medicine [12]. Moreover, pharmacogenomics contributes to the field of predictive oncology, allowing clinicians to anticipate a patient's response to a particular treatment before it is administered. This foresight enables a more proactive and personalized approach, steering away from a trial-and-error methodology and optimizing the selection of therapies based on the individual genetic makeup of the patient and the molecular characteristics of their tumor [13]. As we navigate the complexities of cancer treatment, pharmacogenomics not only enhances therapeutic precision but also holds the promise of reducing the burden of adverse effects and improving the quality of life for individuals undergoing cancer therapy. While challenges such as the need for broader genomic databases and standardized testing protocols persist, the integration of pharmacogenomics into oncology heralds a future where cancer treatment is not only more effective but also more tailored to the unique genetic signatures of each patient.

2.4. Psychiatric medications and genetic markers

The realm of psychiatric medications is characterized by significant variability in treatment response and adverse reactions among individuals. Pharmacogenomics has emerged as a critical tool in unraveling the complex interplay between genetics and psychiatric drug responses. This section explores the dynamic landscape of psychiatric medications and the influence of genetic markers on treatment outcomes. Genetic variations play a pivotal role in the metabolism of psychiatric drugs, impacting the activity of drug-metabolizing enzymes such as those in the cytochrome P450 family [14]. These genetic polymorphisms contribute to the wide range of responses observed in patients, influencing drug efficacy and side effect profiles. Pharmacogenomics testing offers a way to identify these genetic markers, allowing psychiatrists to tailor medication regimens based on an individual's genetic profile. Antidepressants, antipsychotics, and mood stabilizers are among the psychiatric medications affected by genetic variability. For example, variations in the CYP2D6 gene influence the metabolism of selective serotonin reuptake inhibitors (SSRIs), a commonly

prescribed class of antidepressants [15, 16]. Understanding the genetic factors at play can guide clinicians in selecting the most appropriate medication and dosage, thereby optimizing treatment response and minimizing the risk of adverse effects. Pharmacogenomics insights also extend to predicting susceptibility to side effects such as weight gain, metabolic disturbances, and extrapyramidal symptoms associated with certain psychiatric medications. By incorporating genetic information into treatment decisions, psychiatrists can move toward a more personalized and precise approach to mental health care, potentially improving patient adherence and outcomes [17]. While the integration of pharmacogenomics into psychiatric practice is still evolving, the promise of tailoring medication choices based on individual genetic markers holds the potential to revolutionize mental health treatment, ushering in an era of more effective and personalized psychiatric care. Challenges such as the need for broader evidence and standardized testing protocols remain, but the strides made in this field underscore its significance in enhancing the overall well-being of individuals with mental health conditions [18, 19].

2.5. Ethical and legal considerations

As pharmacogenomics advances, the integration of genetic information into healthcare practices raises critical ethical and legal considerations. The ethical dimension encompasses issues such as patient autonomy, informed consent, and the potential for genetic determinism. Implementing pharmacogenomics testing necessitates transparent communication with patients regarding the implications of genetic results on treatment decisions, respecting their right to make informed choices. Privacy concerns are paramount, given the sensitivity of genetic information. Safeguarding genetic data from unauthorized access and ensuring its responsible use are ethical imperatives. Striking a balance between the benefits of personalized medicine and protecting patient privacy poses an ongoing ethical challenge. Moreover, the potential for genetic discrimination poses ethical and legal dilemmas. Concerns arise regarding employment, insurance, and societal stigmatization based on genetic predispositions revealed through pharmacogenomics testing [20]. Policymakers must navigate this complex terrain to enact legislation that safeguards individuals from discriminatory practices while fostering the responsible use of genetic information. From a legal standpoint, ensuring the standardization of testing procedures and the reliability of results is imperative. Regulations must keep pace with scientific advancements to maintain the quality and consistency of pharmacogenomics testing across healthcare settings. Legal frameworks should address issues of liability and accountability, establishing guidelines for clinicians to interpret and apply genetic information responsibly.

2.6. Technological advancements in pharmogenomics

The field of pharmacogenomics has witnessed unprecedented growth, largely propelled by rapid technological advancements that have revolutionized our ability to decipher the intricacies of the human genome. This section explores the cutting-edge technologies that have propelled pharmacogenomics into the forefront of precision medicine. High-throughput sequencing, exemplified by next-generation sequencing (NGS) technologies, has been a game-changer in pharmacogenomics research. These methods allow for the efficient and cost-effective analysis of large volumes of genetic data, enabling the simultaneous examination of numerous genes associated with drug metabolism and response. NGS facilitates comprehensive genomic profiling, offering a more holistic view of an individual's genetic landscape and potential drug interactions. Bioinformatics plays a pivotal role in interpreting the vast amount of genomic data generated by high-throughput sequencing. Advanced computational tools and algorithms are employed to identify relevant genetic variants, predict drug-gene interactions, and assist in clinical decision-making. This integration of bioinformatics expedites the translation of genomic information into actionable insights for healthcare providers. Microarray technology has also been instrumental in pharmacogenomics, allowing for the simultaneous analysis of thousands of genetic markers [21, 22]. This approach provides a snapshot of an individual's genetic variations relevant to drug response, offering a more focused and targeted method for pharmacogenomics testing. CRISPR-Cas9 gene editing technology has opened new avenues for functional genomics in pharmacogenomics research. Researchers can now manipulate specific genes to understand their role in drug metabolism and response, providing invaluable insights into the functional consequences of genetic variations. The emergence of point-of-care testing devices has brought pharmacogenomics applications closer to real-time clinical decision-making. These portable devices enable rapid genetic testing at the patient's bedside, facilitating swift adjustments to treatment plans based on individual genetic profiles. As technological innovations continue to unfold, the pharmacogenomics landscape is poised for further transformation. The integration of these technologies not only enhances our understanding of the genetic factors influencing drug responses but also brings us closer to the realization of truly personalized medicine. Challenges such as data security, standardization, and ethical considerations remain, but the relentless progress in technology assures a future where pharmacogenomics becomes an integral part of routine clinical practice, guiding clinicians in tailoring therapies to individual patients with unprecedented precision [23]

2.7. Cardiovascular medications and genetic predisposition

The administration of cardiovascular medications is often met with a spectrum of responses among individuals, and understanding the role of genetic predisposition in these variations has become a focal point in pharmacogenomics research. One of the key areas of interest is the metabolism of anticoagulants and antiplatelet agents. Genetic polymorphisms in the cytochrome P450 (CYP) enzymes, particularly CYP2C19 and CYP2C9, have been identified as significant contributors to variability in drug metabolism. For instance, the CYP2C19 polymorphism affects the conversion of clopidogrel, a commonly prescribed antiplatelet agent, into its active form. Individuals with certain genetic variants may exhibit reduced efficacy of clopidogrel, leading to a higher risk of cardiovascular

events. Warfarin, a widely used anticoagulant, is another example where genetic factors play a crucial role. Variations in the VKORC1 and CYP2C9 genes influence an individual's response to warfarin and their susceptibility to bleeding complications. Pharmacogenomics testing for these genetic markers can guide clinicians in determining the optimal dosage of warfarin, minimizing the risk of adverse events. Genetic predisposition also extends to the response to drugs like statins, which are commonly prescribed for managing cholesterol levels [24, 25]. Polymorphisms in genes such as SLCO1B1 influence the pharmacokinetics of statins, affecting their efficacy and potential for side effects. Understanding these genetic factors can aid in selecting the most appropriate statin and dosage for individual patients, optimizing cholesterol management. Moreover, genetic markers associated with hypertension and heart failure medications contribute to the overall landscape of cardiovascular pharmacogenomics. Polymorphisms in genes related to drug receptors, transporters, and pathways involved in blood pressure regulation can impact the effectiveness of antihypertensive medications. The integration of pharmacogenomics into cardiovascular care allows for a more personalized approach to medication management. By identifying genetic predispositions, clinicians can tailor treatment regimens to maximize efficacy while minimizing the risk of adverse events. Despite these advancements, challenges persist, including the need for widespread adoption of pharmacogenomics testing in routine clinical practice, establishing standardized guidelines, and addressing issues of healthcare disparities [26]. As pharmacogenomics research continues to unravel the genetic intricacies influencing cardiovascular medication responses, the prospect of individualized treatment plans holds promise for improving patient outcomes and advancing the field of precision cardiovascular medicine. The ongoing exploration of genetic factors in cardiovascular pharmacology not only deepens our understanding of drug response variability but also lays the foundation for a future where cardiovascular care is finely tuned to the unique genetic makeup of each patient

3. Future trends

As pharmacogenomics continues to carve its path towards mainstream clinical practice, several future directions and challenges shape the trajectory of this dynamic field. Achieving seamless integration of pharmacogenomics data into routine clinical workflows represents a pivotal future direction. Streamlining the process of genetic testing, interpretation, and incorporation into treatment decisions is essential for maximizing the impact of pharmacogenomics on patient care. The development and expansion of comprehensive genetic databases are critical for enhancing the accuracy and relevance of pharmacogenomics predictions. As more diverse populations are included in these databases, our understanding of genetic variations and their impact on drug responses will become more robust. Future efforts should focus on enhancing patient education and engagement regarding pharmacogenomics testing [27, 28]. Empowering patients with knowledge about the benefits and implications of genetic testing fosters informed decision-making and promotes active participation in their healthcare. Establishing standardized guidelines and regulatory frameworks is imperative to ensure the consistent and responsible implementation of pharmacogenomics across healthcare settings. Addressing ethical, legal, and privacy concerns requires ongoing collaboration between healthcare professionals, policymakers, and regulatory bodies. Comprehensive education and training programs for healthcare professionals are essential to equip them with the knowledge and skills necessary for integrating pharmacogenomics into clinical practice. Bridging the gap between genomic research and its practical application in patient care is crucial for realizing the full potential of pharmacogenomics. Attention must be directed towards addressing healthcare disparities in the accessibility and affordability of pharmacogenomics testing. Ensuring equitable access to these advancements is essential to prevent exacerbating existing disparities in healthcare outcomes. The field of pharmacogenomics is dynamic, with ongoing research expanding our understanding of genetic contributions to drug responses. Future innovations may include more sophisticated technologies, such as single-cell sequencing, and a deeper exploration of the impact of rare genetic variants on drug metabolism and efficacy [29].

4. Conclusion

In conclusion, the exploration of pharmacogenomics illuminates a transformative path toward precision medicine, promising individualized therapeutic strategies based on genetic profiles. From the optimization of cancer therapies to the nuanced management of psychiatric medications, pharmacogenomics is reshaping the landscape of healthcare. As we unlock the genetic code's secrets, the potential for improved treatment outcomes and minimized adverse effects becomes increasingly tangible. However, challenges such as ethical considerations and standardization persist. Embracing these advances requires ongoing collaboration between researchers, clinicians, and policymakers. The rise of personalized medicine beckons, offering a future where healthcare is not only evidence-based but uniquely tailored to each individual's genetic makeup.

References

[1]   Xinghua Hu S, Foster T, Kieffaber A. Pharmacogenomics and personalized medicine: mapping of future value creation. Biotechniques. 2005 Oct; 39(4S):S1-6.

[2]   Visvikis-Siest S, Gorenjak V, Stathopoulou MG. Personalized medicine: the odyssey from hope to practice. Journal of Personalized Medicine. 2018 Sep 21; 8(4):31.

[3] Spielberg SP. The dawn of pediatric personalized therapeutics. The Journal of Pediatric Pharmacology and Therapeutics. 2010 Jan 1; 15(1):10-6.

[4] Jeibouei S, Akbari ME, Kalbasi A, Aref AR, Ajoudanian M, Rezvani A, Zali H. Personalized medicine in breast cancer: pharmacogenomics approaches. Pharmacogenomics and personalized medicine. 2019 May 27:59-73.

[5] Nandy A, Gangopadhyay S, Mukhopadhyay A. Individualizing breast cancer treatment—The dawn of personalized medicine. Experimental cell research. 2014 Jan 1; 320(1):1-1.

[6] de Leon J. Evidence-based medicine versus personalized medicine: are they enemies? Journal of clinical psychopharmacology. 2012 Apr 1; 32(2):153-64.

[7] Reitman ML, Schadt EE. Pharmacogenetics of metformin response: a step in the path toward personalized medicine. The Journal of Clinical Investigation. 2007 May 1; 117(5):1226-9.

[8] Aziz RK. Interview with Prof. Ramy K. Aziz, Cairo University. The dawn of pharmacomicrobiomics. OMICS: A Journal of Integrative Biology. 2018 Apr 1; 22(4):295-7.

[9] Mai Y, Mitropoulou C, Papadopoulou XE, Vozikis A, Cooper DN, Van Schaik RH, Patrinos GP. Critical appraisal of the views of healthcare professionals concerning pharmacogenomics and personalized medicine in Greece. Personalized Medicine. 2014 Jan; 11(1):15-26.

[10] Zhang G, Nebert DW. Personalized medicine: Genetic risk prediction of drug response. Pharmacology & therapeutics. 2017 Jul 1; 175:75-90.

[11] Hunt LM, Kreiner MJ. Pharmacogenetics in primary care: the promise of personalized medicine and the reality of racial profiling. Culture, Medicine, and Psychiatry. 2013 Mar; 37:226-35.

[12] Češková E, Šilhán P. From Personalized Medicine to Precision Psychiatry? Neuropsychiatric Disease and Treatment. 2021 Dec 14:3663-8.

[13] Mah J. Clinical and Statistical Considerations in Personalized Medicine: edited by Claudio Carini, Sandeep M. Menon, Mark Chang, Boca Raton, FL: Chapman and Hall/CRC, 2014, ISBN 9781466593862, 358 pp., $89.95 (hardcover).

[14] Zhang A, Sun H, Wang P, Han Y, Wang X. Future perspectives of personalized medicine in traditional Chinese medicine: a systems biology approach. Complementary therapies in medicine. 2012 Feb 1; 20(1-2):93-9.

[15] Tutton R. Genomics and the reimagining of personalized medicine. Routledge; 2016 Apr 15.

[16] Mitropoulou C, Politopoulou K, Vozikis A, Patrinos GP. Assessing the stakeholder landscape and stance point on genomic and personalized medicine. InApplied Genomics and Public Health 2020 Jan 1 (pp. 211-223). Academic Press.

[17] Sagia A, Cooper DN, Poulas K, Stathakopoulos V, Patrinos GP. Critical appraisal of the private genetic and pharmacogenomics testing environment in Greece. Personalized medicine. 2011 Jul; 8(4):413-20.

[18] Hu X, Jia T, Zhang X, Wu C, Zhang Y, Chen J, Guan X, Shi L, Lu CY, Nie X. Clinical pharmacists' involvement in pharmacogenomics testing and related services in China. Journal of Personalized Medicine. 2022 Jul 31; 12(8):1267.

[19] Pirmohamed M. Pharmacogenomics: Current status and future perspectives. Nature Reviews Genetics. 2023 Jan 27:1-3.

[20] Ragia G, Manolopoulos VG. From Homer and Hippocrates to modern personalized medicine: is there a role for pharmacogenomics in the treatment of alcohol addiction? Pharmacogenomics. 2018 Apr; 19(6):513-6.

[21] Lim SH, Kim K, Choi CI. Pharmacogenomics of Monoclonal Antibodies for the Treatment of Rheumatoid Arthritis. Journal of Personalized Medicine. 2022 Jul 31;12(8):1265

[22] El-Osta H, Shackelford R. Personalized treatment options for ALK-positive metastatic non-small-cell lung cancer: a potential role for Ceritinib. Pharmacogenomics and personalized medicine. 2015 Sep 29:145-54.

[23] Epstein RS, Frueh FW, Geren D, Hummer D, McKibbin S, O'Connor S, Randhawa G, Zelman B. Payer perspectives on pharmacogenomics testing and drug development.

[24] Vega FM, Dailey D, Ziegle J, Williams J, Madden D, Gilbert DA. New generation pharmacogenomic tools: a SNP linkage disequilibrium Map, validated SNP assay resource, and high-throughput instrumentation system for large-scale genetic studies. Biotechniques. 2002 Jun; 32(sup):S48-54.

[25] Mitropoulou C, Giannouri D, Karamperis K, Wadge S, Patrinos GP. Defining genetic-testing delivery and promotional strategies for personalized medicine. InApplied Genomics and Public Health 2020 Jan 1 (pp. 329-344). Academic Press.

[26] Sarella PN, Gudapati H, Asogwa PO, Kakarparthy R. A Case Report of Heart Failure with Atrial Fibrillation and Peripheral Vascular Resistance. Indian Journal of Pharmacy Practice,. 2023;16(3).

[27]   Herzig AF, Clerget-Darpoux F, Génin E. The false dawn of polygenic risk scores for human disease prediction. Journal of Personalized Medicine. 2022 Jul 31; 12(8):1266.

[28]   Sarella PN, Mangam VT. AI-Driven Natural Language Processing in Healthcare: Transforming Patient-Provider Communication. Indian Journal of Pharmacy Practice. 2024;17(1).

[29]   Greenberger PA. Personalized medicine for patients with asthma. Journal of Allergy and Clinical Immunology. 2010 Feb 1; 125(2):305-6.

Author's short biography

M.K. Vijayalakshmi:

M.K. Vijayalakshmi is working as an Associate Professor in department of Pharmaceutical Chemistry /Analysis at Faculty of Pharmacy, Bharath Institute of Higher Education and Research. She has completed her post-graduation in Pharmaceutical Chemistry in Madaras Medical College, Chennai. She has vast experience in Research and Development in various industries and Organisation. Her present interest on research in Computer Aided Drug Design with strong background in various pharmaceutical field as Quality Control Chemist, Senior Research Scientist and Academic Field. She has published many number of research article in peer reviewed national and international journals and many number of book chapters and also she edited many books

S. Showbharnikhaa:

S.Showbharnikhaa , B.Pharm Final year student at Faculty of Pharmacy, Bharath Institute of Higher Education and Research

T. Akshaya:

T.Akshaya B.Pharm Final year student at Faculty of Pharmacy, Bharath Institute of Higher Education and Research